Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modafinil + nicotine
- Development stage
- Unknown
- Lead developer
- Catherine Martin
- Modality
- Small Molecules
- Administration
- Oral, Transdermal
01
Overview
This investigational combination therapy consists of modafinil, a wakefulness-promoting agent, and nicotine replacement therapy (NRT). Developed by Dr. Catherine Martin at the University of Kentucky, the combination is specifically designed to treat tobacco use disorder in nicotine-dependent adolescent smokers. Modafinil is a small molecule that acts as a psychostimulant, hypothesized to mitigate common nicotine withdrawal symptoms that often lead to cessation failure, such as inattention, depressed mood, increased appetite, and weight gain. By combining modafinil's ability to enhance alertness and reduce cravings with the standard nicotine substitution provided by NRT, the therapy aims to provide a more comprehensive approach to smoking cessation in younger populations.
- Other names
- modafinil and nicotine replacement therapymodafinil and NRTmodafinil + nicotine replacement therapy
02
Targets
TAAR1 (Trace amine-associated receptor 1)Nicotinic Acetylcholine ReceptorSERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on modafinil + nicotine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modafinil + nicotine.